{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F8ca309c7-eae5-4474-bc3a-7f94665f8190","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/8ca309c7-eae5-4474-bc3a-7f94665f8190\"></iframe>","title":"Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor","description":"\n        <p>Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.</p>\n\n<p>CME information and select publications <a href=\"https://researchtopractice.com/InsideTheIssue2023/ERPositivemBC\" rel=\"nofollow\">here</a>.</p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/0c8f63cc-bdef-4a17-90fd-06c89580c835/cover.jpg"}